ClinicalTrials.gg
Not yet recruitingNCT05948982Updated Jul 17, 2023

Safety of Umbilical Cord Mesenchymal Stem Cells (UC-MSC) in Patients With Decompensated Hepatitis B Cirrhosis

A Phase 1/2 interventional study of Human Umbilical Cord Mesenchymal Stem Cells in Decompensated Liver Cirrhosis, sponsored by Asia Cell Therapeutics (Shanghai) Co., Ltd.. Not yet recruiting. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-07-17.

Sponsored by Asia Cell Therapeutics (Shanghai) Co., Ltd. · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
18
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The goal of this clinical trial is to evaluate the safety and tolerability of multiple doses of human umbilical cord mesenchymal stem cell injection in patients with decompensated hepatitis B cirrhosis, and to further explore the efficacy, pharmacodynamic profile and appropriate dose of administration to provide a basis for the use of safer and more effective treatments for patients with decompensated hepatitis B cirrhosis in the future.

Participants are required to sign an informed consent form and, after undergoing a series of tests and meeting the protocol's entry and exclusion criteria, are assigned to a dose group for intravenous infusion of human umbilical cord mesenchymal stem cells.

Read the detailed description

Cirrhosis decompensated stage is an advanced stage of liver disease caused by various chronic liver damages, and 77% of cirrhosis patients in China are caused by hepatitis B virus (HBV). The current treatment for patients with cirrhotic decompensation is mainly symptomatic treatment with drugs targeting the cause, anti-liver fibrosis drugs and supplemental albumin, diuresis, endoscopic sclerosis or ligation, blood purification (artificial liver) and vascular intervention. Although these treatments are effective in slowing down the progression of the disease in patients, they cannot completely reverse the decompensation of liver function in all patients. Currently, liver transplantation remains the most effective treatment for decompensated cirrhosis. However, due to the lack of donor liver sources, only a small number of patients can be treated with transplantation.

In recent years, with the in-depth research in the field of stem cells and regenerative medicine, the therapeutic role of stem cells in end-stage liver disease has received increasing attention based on their biological functions such as tissue damage repair and immune regulation. A large number of clinical exploratory studies on stem cell transplantation for liver diseases have been conducted by scholars in the field, and the published findings suggest that MSC transplantation can improve the liver function index of patients, and the appetite, mental and physical strength of patients improved significantly after infusion.

The investigators hope that the final research results will provide safe, effective and more accessible treatments for more patients in the same category, improve their quality of life and fill the gap in the field of regenerative medicine for the treatment of hepatitis B cirrhosis in the decompensated stage.

The main objective of this study was to evaluate the safety and tolerability of multiple doses of human umbilical cord MSC injection in patients with decompensated hepatitis B cirrhosis, and to further explore the efficacy, pharmacodynamic characteristics and appropriate doses for future use of safer and more effective treatments for patients with decompensated hepatitis B cirrhosis.

The test drug used in this study is called Human Umbilical Cord Mesenchymal Stem Cell Injection, and this study drug is not yet approved for marketing. This product is 10 ml, 1×100000000 cells, packaged in a cell lyophilization bag, and manufactured and supplied by Asia Cell Therapeutics (Shanghai) Co., Ltd.. The excipients of this product include dimethyl sulfoxide (DMSO), human blood albumin (HSA) and compound electrolyte injection. Quality control tests showed that the survival rate of recovered cells after lyophilization was not less than 80% within 6 hours. The cell sterility check, mycoplasma, specific human-derived virus, surface antigen and tumorigenicity were all negative. All quality control results met the requirements of the 2020 version of the Chinese Pharmacopoeia or related testing standards.

Non-clinical and other clinical studies suggest that human umbilical cord MSCs can alter the tissue microenvironment through paracrine mechanisms, provide nutrients and an environment conducive to liver proliferation and repair, promote damaged liver regeneration and liver vascular regeneration, inhibit the proliferation and migration of immune cells to the liver, regulate liver and systemic immune inflammatory responses, thereby reducing liver damage and inhibiting the formation of liver fibrosis. In addition, human umbilical cord MSCs may have the potential to differentiate into hepatocytes (a type of cell with normal hepatocyte function), thereby replenishing damaged liver tissue and improving liver function.

The human umbilical cord MSC injections used in this study have been studied by the National Health Care Commission (NHC)/Central Military Commission (CMC) General Directorate of Health (GMDH) and have accumulated a certain amount of human safety and efficacy data in patients with inhalation lung injury, burn injury and decompensated hepatitis B cirrhosis.

This study was a multiple-dose, open, dose-escalation design. Subjects enrolled in this study will enter the low (1 x 1000000 cells/kg), medium (2 x 1000000 cells/kg), and high (4 x 1000000 cells/kg) dose groups on a sequential entry basis, with each subject receiving only one corresponding dose. The infusion route of human umbilical cord MSC injection is the peripheral vein, and the frequency of treatment is one infusion every 4 weeks, for a total of three infusions, and the subjects will be hospitalized at the study center for 3-7 days after each infusion (the exact duration can be determined by the investigator on a case-by-case basis).

Dosing regimen:

The titration will be completed within 6 hours after the cell preparation has been resuscitated and prepared, the infusion will take no less than 45 minutes, and participants will be closely observed for at least 2 hours after the infusion.

After the first subject in the same dose group has completed 14 days of safety observation after the first dose, the second to sixth subjects in that group may begin dosing on a case-by-case basis, with a minimum of 3 days between enrollment in the high dose group, with the specific interval being adjusted based on the safety data that have been generated. The first subject in the next dose group may be started 28 days after the last subject in the previous dose group completes the first dose. During the dose escalation process, the investigator and sponsor will determine whether to proceed to the next dose group based on the safety data from the previous dose group.

02

Conditions studied

  • Decompensated Liver Cirrhosis

Browse trials for

Keywords

  • Decompensated hepatitis B cirrhosis
  • Human Umbilical Cord Mesenchymal Stem Cells
03

In context

Liver Cirrhosis

1,301 studies on the registry are indexed under Liver Cirrhosis; 341 are open to participants now.

This study's planned enrollment of 18 is below the median of 78 across 742 interventional studies indexed under Liver Cirrhosis.

Browse Liver Cirrhosis studies →

Lead sponsor

Asia Cell Therapeutics (Shanghai) Co., Ltd. is the lead sponsor of 3 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 to 75 years old (including borderline values) at screening, regardless of gender
  • Diagnosed with decompensated cirrhosis according to the Guidelines for the Prevention and Treatment of Chronic Hepatitis B (2019 edition)
  • There's no significant reduction in cirrhotic symptoms or no significant improvement in quality of life score after more than 3 months of strict medical conservative treatment
  • HBV DNA ≤ 1000 IU/mL at the time of screening
  • Fully understand the form, voluntarily subject to the trial and sign the informed consent form.

Exclusion criteria

Exclusion Criteria:

  • other causes of cirrhosis, such as alcoholic hepatitis, viral , hepatitis and metabolic-related fatty liver disease
  • score >12;
  • History of of the liver or other organs, or a family history of liver malignancy in three generations of immediate family members;
  • Current serious medical conditions that would affect your safety and treatment efficacy assessment as determined by the investigator, such as: Class II or higher abnormal cardiac function ( criteria), cardiovascular disease such as ischemic heart disease (e.g., myocardial infarction or angina), poorly controlled diabetes (fasting glucose ≥ 10 mmol/L or (HbA1c) ≥ 8%), serum creatinine > 2 times the (ULN), etc;
  • Recent uncontrolled gastrointestinal bleeding (e.g., severe bleeding tendency or active bleeding within 3 months prior to screening, or upper gastrointestinal hemorrhage event within 4 weeks prior to screening), as determined by the investigator to be unsuitable for participation in this trial;
  • Have had hepatic encephalopathy or hepatorenal syndrome within 3 months prior to screening
  • Spontaneous peritonitis or a more severe active infection within 2 weeks prior to the trial
  • Positive infectious disease test (serum anti- antibody, anti-HCV antibody, syphilis antibody either positive) or active tuberculosis;
  • Those who have received human albumin within 3 weeks prior to the first infusion of the test drug;
  • Those who have the history of venous thrombosis or pulmonary embolism
  • Drug addicted or alcohol abusers;
  • Women who are pregnant or breastfeeding;
  • Persons with a history of severe drug allergy or ;
  • History of a serious mental disorder, including uncontrolled major depression or controlled or uncontrolled psychosis, within 24 months prior to screening;
  • Those who have participated in other interventional clinical trials within 3 months prior to screening or are participating in other interventional clinical trials, or who have received prior stem cell therapy
  • Those who are proposed for liver transplantation within 3 months;
  • Other conditions that, in the opinion of the investigator, are not suitable for participation in this clinical trial.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
18 participants (estimated)

Study arms

  • Experimental
    Human Umbilical Cord Mesenchymal Stem Cells

    The trial was divided into three dose groups: Low-dose group: 1000000 cells/kg Medium-dose group: 2000000 cells/kg High-does group: 4000000 cells/kg

    Biological: Human Umbilical Cord Mesenchymal Stem Cells

Interventions

  • The stem cell infusion route is peripheral intravenous infusion, once every 4 weeks for a total of 3 infusions. All subjects received experimental drugs and conventional treatment during the study period.

06

What researchers measure

Primary outcomes

  1. Adverse Event (AE)

    Adverse events that occurred during the trials

    Time frame: Through study completion, an average of 1 year

  2. Serious Adverse Event (SAE)

    Serious adverse events that occurred during the trial

    Time frame: Through study completion, an average of 1 year

  3. Recommended dose for phase 2 clinical trial (RP2D)

    Recommended dose for phase 2 clinical trial

    Time frame: Through study completion, an average of 1 year

  4. Dose-limiting toxicity (DLT)

    Dose-limiting toxicity

    Time frame: Through study completion, an average of 1 year

  5. Maximum Tolerated Dose (MTD)

    Maximum Tolerated Dose

    Time frame: Through study completion, an average of 1 year

Secondary outcomes

  1. Overall survival

    Time of survival

    Time frame: Through study completion, an average of 1 year

  2. Rate of survival

    Rate of survival without liver transplantation

    Time frame: Through study completion, an average of 1 year

  3. Child-Pugh

    The Child-Pugh score included a score for five indicators: hepatic encephalopathy, ascites, total bilirubin concentration, albumin concentration, and prothrombin time extension. For each indicator, the lowest score is 1, the highest score is 3, and the total score of each indicator is calculated. A higher score indicates more severe disease.

    Time frame: Day -14 - Day -1, Day -1, Day 28, Day 56, Week 12, Week 20, Week 32, Week 56

  4. MELD

    The Model for End-stage Liver Disease is a scoring system based on serum creatinine, international standardized ratio, total bilirubin combined with the cause of cirrhosis to evaluate the liver function reserve and prognosis of patients with chronic liver disease. Calculating formula for R = 3.78 \* ln \[T - Bil (umol/L) / 17.1\] ln (INR) + 9.57 + 11.2 \* \* ln Cr (umol/L) / 88.4 + 6.43 \* the etiology. (Etiology: 0 for cholestatic cirrhosis and alcoholic cirrhosis, 1 for viral and other causes)

    Time frame: Day -14 - Day -1, Day -1, Day 28, Day 56, Week 12, Week 20, Week 32, Week 56

  5. Hepatic stiffness

    Based on transient elastography fibroscan, observe the liver stiffness.

    Time frame: Day -14 - Day -1, Week 12, Week 20, Week 32, Week 56

  6. Alanine aminotransferase (ALT)

    The concentration of ALT

    Time frame: Day -14 - Day -1, Day -1, Day 1, Day 28, Day 29, Day 56, Day 57, Week12, Week 20, Week 32, Week 56

  7. Aspartate aminotransferase (AST)

    The concentration of AST

    Time frame: Day -14 - Day -1, Day -1, Day 1, Day 28, Day 29, Day 56, Day 57, Week12, Week 20, Week 32, Week 56

  8. Total bilirubin (TBIL)

    The concentration of TBIL

    Time frame: Day -14 - Day -1, Day -1, Day 1, Day 28, Day 29, Day 56, Day 57, Week12, Week 20, Week 32, Week 56

  9. γ-glutamyl transpeptidase (γ-GT)

    The concentration of γ-GT

    Time frame: Day -14 - Day -1, Day -1, Day 1, Day 28, Day 29, Day 56, Day 57, Week12, Week 20, Week 32, Week 56

  10. Alkaline phosphatase (ALP)

    The concentration of ALP

    Time frame: Day -14 - Day -1, Day -1, Day 1, Day 28, Day 29, Day 56, Day 57, Week12, Week 20, Week 32, Week 56

  11. Albumin (ALB)

    The concentration of ALB

    Time frame: Day -14 - Day -1, Day -1, Day 1, Day 28, Day 29, Day 56, Day 57, Week12, Week 20, Week 32, Week 56

  12. Cholinesterase (CHE)

    The concentration of CHE

    Time frame: Day -14 - Day -1, Day -1, Day 1, Day 28, Day 29, Day 56, Day 57, Week12, Week 20, Week 32, Week 56

  13. International Normalized Ratio (INR)

    INR was calculated by the PT ratio of the reference plasma measured by thrombin to normal plasma and the ISI value marked by the reagent used. The higher the INR, the longer it takes for blood to clot

    Time frame: Day -14 - Day -1, Day -1, Day 1, Day 28, Day 29, Day 56, Day 57, Week 12, Week 20, Week 32, W56

  14. Cluster of differentiation 3 (CD3)

    The concentration of CD3

    Time frame: Day -14-Day -1, Day 28, Day 56, Week 12, Week 20, Week 32, Week 56

  15. Cluster of differentiation 4 (CD4)

    The concentration of CD4

    Time frame: Day -14-Day -1, Day 28, Day 56, Week 12, Week 20, Week 32, Week 56

  16. Cluster of differentiation 8 (CD8)

    The concentration of CD8

    Time frame: Day -14-Day -1, Day 28, Day 56, Week 12, Week 20, Week 32, Week 56

  17. Regulatory T cells (Treg)

    The concentration of Treg

    Time frame: Day -14-Day -1, Day 28, Day 56, Week 12, Week 20, Week 32, Week 56

  18. Helper T cell 17 (Th17)

    The concentration of Th17

    Time frame: Day -14-Day -1, Day 28, Day 56, Week 12, Week 20, Week 32, Week 56

  19. Immunoglobulin A (IgA)

    The concentration of IgA

    Time frame: Day -14-Day -1, Day 28, Day 56, Week 12, Week 20, Week 32, Week 56

  20. Immunoglobulin G (IgG)

    The concentration of IgG

    Time frame: Day -14-Day -1, Day 28, Day 56, Week 12, Week 20, Week 32, Week 56

  21. Immunoglobulin M (IgM)

    The concentration of IgM

    Time frame: Day -14-Day -1, Day 28, Day 56, Week 12, Week 20, Week 32, Week 56

  22. Immunoglobulin E (IgE)

    The concentration of IgE

    Time frame: Day -14-Day -1, Day 28, Day 56, Week 12, Week 20, Week 32, Week 56

  23. Alpha-Fetoprotein (AFP)

    The concentration of AFP

    Time frame: Day -14-Day -1, Week 12, Week 20, Week 32, Week 56

  24. Alpha-Fetoprotein-L3 (AFP-13)

    The concentration of AFP-L3

    Time frame: Day -14-Day -1, Week 12, Week 20, Week 32, Week 56

  25. Carcinoembryonic antigen (CEA)

    The concentration of CEA

    Time frame: Day -14-Day -1, Week 12, Week 20, Week 32, Week 56

  26. Carbohydrate antigen (CA19-9)

    The concentration of CA19-9

    Time frame: Day -14-Day -1, Week 12, Week 20, Week 32, Week 56

  27. Carbohydrate antigen 15-3 (CA15-3 )

    The concentration of CA15-3

    Time frame: Day -14-Day -1, Week 12, Week 20, Week 32, Week 56

  28. Protein Induced by Vitamin K Absence or Antagonist-II (PIVKA II)

    The concentration of PIVKA II

    Time frame: Day -14-Day -1, Week 12, Week 20, Week 32, Week 56

  29. Incidence of liver cancer

    Calculate the number of subjects who developed liver cancer during the trial after drug administration as a percentage of all subjects

    Time frame: Through study completion, an average of 1 year

  30. HBV-DNA

    The concentration of HBV-DNA

    Time frame: Day -14-Day -1, Day 28, Day 56, Week 12, Week 20, Week 32, Week 56

  31. Eastern Cooperative Oncology Group (ECOG)

    The ECOG score is an indicator of a patient's general health and ability to tolerate treatment from their physical strength. The ECOG physical condition scoring standard scores 0-5 points. The higher the score is, the worse the physical condition of patient is.

    Time frame: Day -14-Day -1, Week 12, Week 20, Week 32, Week 56

  32. Incidence of complications associated with decompensated cirrhosis

    Diagnosis and severity assessment of complications

    Time frame: Through study completion, an average of 1 year

  33. Incidence of hepatic failure

    Proportion of subjects who developed liver failure

    Time frame: Through study completion, an average of 1 year

  34. SF-36 Quality of Life Score

    The 36-item Short-Form Health Questionnaire (SF-36) is a universal measurement scale developed by the Medical Outcomes Study (MOS) in the United States. It consists of 36 entries covering eight areas: physical function, physical role, physical pain, general health, vitality, social function, emotional role, and mental health. Each section is scored from 0 to 100 points. The score directly reflects the quality of health, the higher the score, the better the function of this aspect, the higher the quality of life.

    Time frame: Day -14-Day -1, Day -1, Day 28, Day 56, Week 12, Week 20, Week 32, Week 56

  35. Chronic Liver Disease Questionnaire

    The Chronic Liver Disease questionnaire was designed to measure the overall body feeling of the participants within the last two weeks. The total score of the questionnaire ranges from 29 points to 203 points, and the lower the score, the worse the physical condition

    Time frame: Day -14-Day -1, Day -1, Day 28, Day 56, Week 12, Week 20, Week 32, Week 56

  36. EQ-5D-5L

    Health questionnaire about subjects' condition.

    Time frame: Day -14-Day -1, Day -1, Day 28, Day 56, Week 12, Week 20, Week 32, Week 56

Other outcomes

  1. IL-1β (Interleukin-1β)

    The concentration of IL-1β

    Time frame: Day 1, Day 2, Day 3, Day 7, Day 28, Day 29, Day 30, Day 31, Day 35, Day 56, Day 57, Day 58, Day 59, Day 64, Day 85, Week 12, Week 20, Week 32, Week 56

  2. IL-6 (Interleukin-6)

    The concentration of IL-6

    Time frame: Day 1, Day 2, Day 3, Day 7, Day 28, Day 29, Day 30, Day 31, Day 35, Day 56, Day 57, Day 58, Day 59, Day 64, Day 85, Week 12, Week 20, Week 32, Week 56

  3. IL-8 (Interleukin-8)

    The concentration of IL-8

    Time frame: Day 1, Day 2, Day 3, Day 7, Day 28, Day 29, Day 30, Day 31, Day 35, Day 56, Day 57, Day 58, Day 59, Day 64, Day 85, Week 12, Week 20, Week 32, Week 56

  4. IL-8 (Interleukin-10)

    The concentration of IL-10

    Time frame: Day 1, Day 2, Day 3, Day 7, Day 28, Day 29, Day 30, Day 31, Day 35, Day 56, Day 57, Day 58, Day 59, Day 64, Day 85, Week 12, Week 20, Week 32, Week 56

  5. IL-8 (Interleukin-12)

    The concentration of IL-12

    Time frame: Day 1, Day 2, Day 3, Day 7, Day 28, Day 29, Day 30, Day 31, Day 35, Day 56, Day 57, Day 58, Day 59, Day 64, Day 85, Week 12, Week 20, Week 32, Week 56

  6. IL-8 (Interleukin-17)

    The concentration of IL-17

    Time frame: Day 1, Day 2, Day 3, Day 7, Day 28, Day 29, Day 30, Day 31, Day 35, Day 56, Day 57, Day 58, Day 59, Day 64, Day 85, Week 12, Week 20, Week 32, Week 56

  7. TNF-α (Tumor necrosis factor-α)

    The concentration of TNF-α

    Time frame: Day 1, Day 2, Day 3, Day 7, Day 28, Day 29, Day 30, Day 31, Day 35, Day 56, Day 57, Day 58, Day 59, Day 64, Day 85, Week 12, Week 20, Week 32, Week 56

  8. TGF-β (Transforming growth factor-β)

    The concentration of TGF-β

    Time frame: Day 1, Day 2, Day 3, Day 7, Day 28, Day 29, Day 30, Day 31, Day 35, Day 56, Day 57, Day 58, Day 59, Day 64, Day 85, Week 12, Week 20, Week 32, Week 56

  9. IFN-γ (Interferon-γ)

    The concentration of IFN-γ

    Time frame: Day 1, Day 2, Day 3, Day 7, Day 28, Day 29, Day 30, Day 31, Day 35, Day 56, Day 57, Day 58, Day 59, Day 64, Day 85, Week 12, Week 20, Week 32, Week 56

  10. SDF-1 (Stromal cell-derived factor-1)

    The concentration of SDF-1

    Time frame: Day 1, Day 2, Day 3, Day 7, Day 28, Day 29, Day 30, Day 31, Day 35, Day 56, Day 57, Day 58, Day 59, Day 64, Day 85, Week 12, Week 20, Week 32, Week 56

  11. CRP (C-reaction protein)

    The concentration of CRP

    Time frame: Day 1, Day 2, Day 3, Day 7, Day 28, Day 29, Day 30, Day 31, Day 35, Day 56, Day 57, Day 58, Day 59, Day 64, Day 85, Week 12, Week 20, Week 32, Week 56

  12. MMP-9 (Matrix metalloprotein-9)

    The concentration of MMP-9

    Time frame: Day 1, Day 2, Day 3, Day 7, Day 28, Day 29, Day 30, Day 31, Day 35, Day 56, Day 57, Day 58, Day 59, Day 64, Day 85, Week 12, Week 20, Week 32, Week 56

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jul 2023; primary completion for Dec 2026, 41 months later.

How these figures are worked out, and which studies are left out of them.

Registered
May 25, 2023
First posted
Jul 17, 2023
StartEst.
Jul 30, 2023
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Jul 17, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 17, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05948982
Lead sponsor
Asia Cell Therapeutics (Shanghai) Co., Ltd.
Responsible party
Sponsor
First posted
Jul 17, 2023
Start date
Jul 30, 2023 (estimated)
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Jul 17, 2023

Study contacts

Wenli Liu
Contact
liuwenli@xibaozhiliao.cn
+86 13402137712
Lungen Lu, MD
principal investigator · Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Solizmestrocel

Start the discussion